We would love to hear your thoughts about our site and services, please take our survey here.
Apologies if seen already, Sir John Bell talks about 4 promising LFT's in validation process to help us get up to 5 million tests/day.
Around 59:30 starts talking about them
https://youtu.be/tSYz5emEQKg
I think the GSK reference is the collaboration with novacyt astrazeneca and cambridge uni to automate testing, increase use of robots and increase throughout. Was mentioned in April as part of 5 pillars.
https://www.faron.com/pipeline/traumakine-fp-1201-lyo
Hydrocortisone inhibited interferon beta 1a in phase 3 trial here. Great news inhaled version doesn't have the same problem especially with hydrocortisone and dexamethasone being approved to treat covid
Medimmune account for over half of astrazeneca's R&D portfolio and although their brand has now gone they are based in Maryland rather than DC. But like PJMH said, Maryland has trended highly on Google also. It's a long shot...
Dave the headquarters of NIH are 10 miles out of Washington DC so could explained the high volume of Google searches in this area. There are some major pharmas that have offices in DC, but my feeling it's NIH as these are their headquarters.
The rapid tests he was talking about being available soonest were where a van would travel to where the tests needed to be taken. Would this be optigene then? They going to need a lot of vans to make this a rapid service!! He talked about other rapid saliva tests in the pipeline. Although we won't be the first 'rapid' saliva test, we should be the first rapid antigen saliva test using lft...
https://www.thetimes.co.uk/article/routine-mass-coronavirus-testing-hailed-as-route-back-to-normal-life-nnxbr22lb
Big section in the times today too. Don't think it's us though personally in the Southampton trials but it could be similar to Heathrow where they are just testing the viability of the method.
Merchant - Abbott's mcap went up $27 billion when they announced their nasal swab prescription only, lateral flow test. That was based on their ability to produce 50 million per month at $5 per test. Trump order $750 millions worth immediately. I think that gives avacta shareholders some comfort that there's some value and demand for these tests....if the sensitivity and specificity is up to scratch for avatcas test, we COULD have the best antigen lft in the world.
Intervention Name : Interferon beta-1a
Intervention Description : Patients in the hospital setting will be randomised to one of two treatment groups (SNG001 or placebo) in a 1:1 ratio according to a pre-specified randomisation schedule in addition to standard of care. In the home setting, the device will also be included within the randomisation schedule and the patients will be randomised to one of four groups (Ultra/ SNG001, Ultra/placebo, I-neb/SNG001 or I-neb/placebo) in a 1:1:1:1 ratio.
SNG001 nebuliser solution is presented in glass syringes containing 0.65 ml of drug product solution containing 12 MIU/ml of IFN-ß1a. The I-neb nebuliser is fitted with a 0.53 ml chamber is filled with the contents of one syringe. The Ultra device is filled with the contents of two syringes. Patients inhale one dose per day for 14 days.
The placebo will be the same formulation as the study medication but without IFN-ß1a (i.e. only the excipients of the SNG001 solution) and will be administered once daily via the I-neb or Ultra nebuliser.
Patients are followed up for 14 days (+/- 3 days) after the patient’s last dose or when the last dose of study medication would have been administered if dosing was stopped (for example if the patient was ventilated).
That be part of research indicates there are 4 groups in the new trial...randomisation schedule and the patients will be randomised to one of four groups (Ultra/ SNG001, Ultra/placebo, I-neb/SNG001 or I-neb/placebo) in a 1:1:1:1 ratio.
The i-neb has one syringe and the ultra has 2 syringes so double dose. Is this new? I don't recall there being 4 groups originally.
Also there are now 12 sites rather than 9 that are carrying out the tests.
Chet.theden, it's less of an issue for NHS practices because they are being paid anyway, it's the private practices that it should help if we can reduce/remove the fallow time and open up waiting rooms.
Talk of four further tests including saliva based antigen tests for dental practices further down the line
Great find Joey, my initial feeling is how are they paying for potentially another 600 or so patients without a placing. This surely would have happened prior to these changes to the trial if it was going to happen.
My understanding is that the pilot phase of the hospital setting is complete (phase II results), we have the stellar results for those so I'm assuming they are in a position to decide now whether or not it's an extra 100 patients, 300 patients or somewhere in between. With such incredible results my expectation is at the lower end of this. We are anticipating even better home trial results when they come so this should be similar.
On a side note, I noticed on the updates that anorexia is monitored under clinical improvements for symptomatic patients. Not heard that one before. Also I feel like they've added a new continuous cough and loss of taste/smell to the 'co morbidities' section for patients that can be recruited over 50 years of age in the home trials. This should increase the numbers being allowed in the trial.
Still awaiting COPD results, if good we can stop thinking that the SP is going anywhere below where we are now.